|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:category
|
Chemical company
Life sciences company
|
|
gptkbp:CEO
|
gptkb:Pierre-Alain_Ruffieux
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:founded
|
1897
|
|
gptkbp:founder
|
gptkb:Lonza_Group
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lonza AG
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
CH0013841017
|
|
gptkbp:keyPerson
|
Albert M. Baehny (Chairman)
|
|
gptkbp:logo
|
Lonza_Logo.svg
|
|
gptkbp:notableProject
|
COVID-19 vaccine manufacturing partnership with Moderna
|
|
gptkbp:numberOfEmployees
|
~17,000
|
|
gptkbp:parentCompany
|
gptkb:Lonza_Group
|
|
gptkbp:products
|
biotechnology products
custom manufacturing
pharmaceutical ingredients
|
|
gptkbp:revenue
|
CHF 6.2 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:LONN
|
|
gptkbp:subsidiary
|
gptkb:Capsugel
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.lonza.com/
|
|
gptkbp:bfsParent
|
gptkb:Lonza_River
|
|
gptkbp:bfsLayer
|
7
|